Zakrzewski Joseph S — SEC Form 4 filings
SEC reporting owner CIK 1331852. 11 Form 4 filings on record with FilingPulse; latest filed 2026-08-14.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-01-19 to 2026-08-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 2 filings — 27,000 shares, $27,846 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 100,000 shares, $1,911,410 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 100,000 shares @ $19.11 ($1,911,410) in AN2 Therapeutics, Inc., filed 2024-01-19.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | Director | 10 | 3 legs · 27,000 sh · $27,846 | 1 leg · 100,000 sh · $1,911,410 | 12 |
| Cyteir Therapeutics, Inc. (CYT) | Director | 1 | — | — | 2 |
Form 4 filings — Zakrzewski Joseph S
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | AN2 Therapeutics, Inc. (ANTX) | Gift (G): 405,880 @ $0 | EDGAR |
| 2026-03-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 99,999 (derivative) · Disposition to issuer (D): 99,999 (derivative) · Grant/award (A): 10,362 (derivative) · Disposition to issuer (D): 10,362 (derivative) · Grant/award (A): 23,742 (derivative) · Disposition to issuer (D): 23,742 (derivative) | EDGAR |
| 2026-02-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 19,111 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 10,523 @ $0 | EDGAR |
| 2024-12-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 9,816 @ $0 | EDGAR |
| 2024-11-27 | 4 | AN2 Therapeutics, Inc. (ANTX) | Purchase (P): 2,000 @ $1.40 | EDGAR |
| 2024-11-20 | 4 | AN2 Therapeutics, Inc. (ANTX) | Purchase (P): 20,000 @ $1.00 · Purchase (P): 5,000 @ $1.01 | EDGAR |
| 2024-06-21 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 64,503 (derivative) @ $0 | EDGAR |
| 2024-02-08 | 4 | Cyteir Therapeutics, Inc. (CYT) | Option exercise (M): 14,150 @ $1.69 · Option exercise (M): 14,150 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 100,000 @ $19.11 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1331852 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →